Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has earned a consensus rating of “Buy” from the twenty-eight research firms that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $196.95.
VRTX has been the subject of a number of research reports. Raymond James initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, October 2nd. They set a “buy” rating for the company. Cantor Fitzgerald initiated coverage on Vertex Pharmaceuticals in a research note on Monday, October 1st. They set an “overweight” rating and a $217.00 price target for the company. BidaskClub raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, Argus increased their price target on Vertex Pharmaceuticals to $200.00 and gave the company an “average” rating in a research note on Tuesday, August 28th. They noted that the move was a valuation call.
VRTX opened at $181.32 on Wednesday. Vertex Pharmaceuticals has a 12 month low of $136.50 and a 12 month high of $194.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67. The company has a market capitalization of $49.26 billion, a P/E ratio of 226.65, a price-to-earnings-growth ratio of 1.96 and a beta of 1.48.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.40 by $0.54. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. The firm had revenue of $752.20 million for the quarter, compared to analysts’ expectations of $680.86 million. During the same period last year, the firm earned $0.39 EPS. The firm’s revenue was up 38.2% compared to the same quarter last year. As a group, research analysts expect that Vertex Pharmaceuticals will post 2.48 earnings per share for the current fiscal year.
In other news, SVP Paul M. Silva sold 860 shares of the firm’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $179.85, for a total transaction of $154,671.00. Following the completion of the sale, the senior vice president now directly owns 16,947 shares of the company’s stock, valued at approximately $3,047,917.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Stuart A. Arbuckle sold 10,083 shares of the firm’s stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $175.29, for a total value of $1,767,449.07. Following the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at $8,567,649.33. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,560 shares of company stock valued at $7,436,746. Corporate insiders own 0.75% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mount Yale Investment Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth $101,000. Kaizen Advisory LLC boosted its stake in shares of Vertex Pharmaceuticals by 147.3% during the 2nd quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock worth $102,000 after acquiring an additional 358 shares in the last quarter. Sun Life Financial INC boosted its stake in shares of Vertex Pharmaceuticals by 266.1% during the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after acquiring an additional 503 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Vertex Pharmaceuticals by 3,126.1% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock worth $126,000 after acquiring an additional 719 shares in the last quarter. 93.47% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Featured Story: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.